-
An experimental anti-HIV tenofovir gel is safe for women to use on a daily basis, according to research conducted by the scientists at the University of Pittsburgh (PA) School of Medicine and the University of Alabama at Birmingham (UAB).
-
Bad news: Results of the first large-scale effectiveness trial for a microbicide indicate that while the candidate, Carraguard, is safe, it was not shown to be effective in preventing male-to-female transmission of HIV.
-
Be sure to pencil in dates for two upcoming women's health conferences sponsored by the Association of Reproductive Health Professionals, Planned Parenthood Federation, the Society of Family Planning, and the National Association of Nurse Practitioners in Women's Health (NPWH).
-
Check the next four files of your teenage female patients: chances are one of these young women has a sexually transmitted disease (STD), according to study results just released by the Centers for Disease Control and Prevention (CDC).
-
Early research indicates that beneficial bacteria found in the healthy vagina aids in reducing the amount of vaginal HIV among HIV-infected women and may make it more difficult for the virus to spread.
-
Are you talking to your patients about pelvic floor disorders (PFDs)? You should. Results from a study of 4,000 U.S. women ages 25-84 indicate one-third of them reported one or more pelvic floor disorders.
-
-
The incidence of back pain in children is directly proportional to the age of the child, with back pain an unusual complaint in children younger than age 6. There is a steady increase in incidence, with adolescents having the highest rates of back pain by the time they are age 18. Approximately 60% of adults experience significant back pain in their lifetimes.
-
-
Does erythropoietin worsen cancer death rates? Most hypothyroid patients can be replaced with levothyroxine alone without additional T3. Does aggressive control in type 2 diabetes save lives?
